evogliptin evogliptin evogliptin (inn; trade names suganon, evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (dpp-4) inhibitor or "gliptin" class of drugs. it was developed by the south korean pharmaceutical company dong-a st and is approved for use in south korea and russia. in a meta-analysis involving data from 6 randomized controlled trials (887 patients), dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other dpp4 inhibitors like sitagliptin and linagliptin. evogliptinclinical datatrade namessuganonother namesda-1229routes ofadministrationby mouthatc codea10bh07 (who) identifiers iupac name (3r)-4--3--2-piperazinone cas number1222102-29-5pubchem cid25022354chemspider26339341unii09118300l7keggd11023chemblchembl1779710comptox dashboard (epa)dtxsid00153545 chemical and physical dataformulac19h26f3n3o3molar mass401.430 g·mol−13d model (jsmol)interactive image smiles cc(c)(c)oc1c(=o)nccn1c(=o)c(cc2cc(c(cc2f)f)f)n inchi inchi=1s/c19h26f3n3o3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16h,4-6,8,10,23h2,1-3h3,(h,24,27)/t12-,16-/m1/s1key:lcddagsjhkeabn-mlgollrusa-n